PGO0.F Prostatype Genomics AB (publ)
- Market cap
- EUR 685K
- P/E
- -
- P/B
- 6.40x
- ROE
- -167.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is PGO0.F undervalued?
Graham numberThe Graham number of Prostatype Genomics AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Prostatype Genomics AB (publ) fundamental analysis
No fundamental analysis for Prostatype Genomics AB (publ) yet.
Prostatype Genomics AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Prostatype Genomics AB (publ)
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctor…
Full company profileProstatype Genomics AB (publ) financial statements
Prostatype Genomics AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 10.0K | 683K | 1.36M | 199K | 594K |
| Gross Profit | 2.51M | 683K | 3.73M | 1.92M | 594K |
| Operating Income | -15.5M | -28.7M | -39.2M | -40.9M | -38.9M |
| EBITDA | - | -26.8M | -38.0M | -37.4M | -40.7M |
| Net Income | -15.6M | -29.1M | -41.4M | -41.1M | -44.5M |
| EPS | -57 | -69 | -22 | -1.26 | -0.29 |
| Balance Sheet | |||||
| Total Assets | 40.2M | 31.0M | 49.2M | 42.0M | 50.9M |
| Total Liabilities | 4.30M | 4.80M | 24.5M | 8.50M | 24.3M |
| Shareholders' Equity | 35.9M | 26.2M | 24.7M | 33.5M | 26.5M |
| Cash & Short-term Investments | 9.83M | 4.81M | 2.68M | 9.42M | 9.07M |
| Cash Flow | |||||
| Operating Cash Flow | -16.1M | -27.7M | -29.1M | -44.7M | -23.8M |
| Capital Expenditure | 2.50M | 0.00 | 8.56M | 7.86M | 13.4M |
| Free Cash Flow | -18.6M | -27.7M | -37.7M | -52.6M | -37.2M |
| Ratios | |||||
| ROE | -43.5% | -111.2% | -167.9% | -122.7% | -167.7% |
| ROA | -38.9% | -94.0% | -84.2% | -97.8% | -87.5% |
| Net Profit Margin | -156,282.0% | -4,258.7% | -3,055.7% | -20,628.6% | -7,492.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Prostatype Genomics AB (publ) dividends
Prostatype Genomics AB (publ) has not paid dividends in the last 5 fiscal years.
Last stock split: 1:1000 on Oct 31, 2024.
Who owns Prostatype Genomics AB (publ)
- Insiders 34.63%
- Institutions 4.18%
- Public & others 61.19%
- Shares outstanding 156M
- Free float 545M
Prostatype Genomics AB (publ) company profile
- Company name
- Prostatype Genomics AB (publ)
- Ticker
- PGO0.F
- ISIN
- SE0023261532
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 7
- Fiscal year end
- December
- Address
- Augustendalsvägen 20, Nacka, Sweden, 131 52
- Phone
- 46 08 20 87 00
- Website
- prostatypegenomics.com
About Prostatype Genomics AB (publ)
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, RTqPCR kit, patient database and algorithms, Prostatype Web System (PWS), and tumor stage, as well as calculates the P-score. Its test is based on a database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Nacka, Sweden.
Prostatype Genomics AB (publ) management
10- Mr. Fredrik RickmanCEO & MD
- Mr. Anders KochChief Financial Officer · born 1973
- George SkinnerVice President Commercial operations
- Ms. Emelie BerglundChief Technology Officer
- Mr. Nicklas RosendalCommunications Director
- Joakim SoderinChief Auditor
- Prof. Gerald L. Andriole Jr., M.D.Global Chief Medical Officer
- Katarina SjöbergHead of RA and QA
- Mr. Steven GaalPresident of US operations
- Mats BergströmSales Director of EMEA